Dr Deborah Rathjen BSc (Hons), PhD, MAICD
(CEO and Managing Director)
A seasoned biotech executive of over 20 years, Dr Deborah Rathjen joined Bionomics in June 2000 from Peptech Limited, where she was Manager of Business Development and Licensing. Dr Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defence of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. Dr Rathjen has significant experience in research, business development and licensing. Dr Rathjen is Chairperson of the AusBiotech Board, and in 2004 was awarded the AusBiotech President's Medal for her significant contribution to the Australian biotechnology industry. In 2006 she received a Distinguished Alumni Award from Flinders University, in 2009 the BioSingapore Asia Pacific Woman Entrepreneur of the Year, and in 2010 Bio Innovation SA Industry Leader Award.
Ms Melanie Young BCom, CA
(Chief Financial Officer and Company Secretary)
Ms Young has over 13 year's experience, with six years in the medical device field, including two years as CFO of an ASX-listed company covering all facets of the company's global finance function. In particular, her considerable commercial experience in listed company reporting requirements, international finances and working capital management will complement the Bionomics team. Ms Young has also gained experience in negotiating distributor agreements, due diligence, cost reduction strategies and improving operating efficiencies. Previously Ms Young worked for Deloitte Touche Tohmatsu in the Growth Solutions Division. Ms Young holds a Bachelor of Commerce from Deakin University and is a Chartered Accountant.
Dr Jose Iglesias MD
(Chief Medical Officer)
Dr Iglesias, commencing employment on 1 November 2012, is a seasoned medical professional with 22 years global experience in the biopharmaceutical industry. He has spent the past six years at Celgene Corporation and its wholly owned subsidiary Abraxis Bioscience as VP of Clinical Development for Celgene with previous roles including CMO and VP of Global Clinical Development and Medical Affairs at Abraxis. Previously, Dr Iglesias worked in several positions at US pharmaceutical giant Eli Lilly over 10 years, including his appointment as Oncology Medical Advisor for the Australia and the Asia Pacific region between 2002 and 2004. A graduate from the Montevideo School of Medicine, Dr Iglesias has been published more than 50 times and is an active member of ASCO, AACR and ESMO.
Dr Emile Andriambeloson PhD
(Head of Research Neurofit)
Dr Emile Andriambeloson joined Neurofit in 2002 from Novartis Pharma and has played an important role in the development of Neurofit's business. In 2005 Dr Andriambeloson became the Head of Research at Neurofit and is the key interface with Neurofit's international customer base as well as Bionomics' CNS programs. Dr Andriambeloson has a PhD from the University of Strasbourg in France and is recognised for his expertise in pharmacology. He is the author of 22 articles published in highly regarded peer reviewed scientific journals. Dr Andriambeloson's previous positions include Novartis Pharma (Basel, Switzerland), Heart Research Institute (Sydney, Australia) and University of New South Wales (Sydney, Australia).
Dr Forrest H Fuller BSC, PhD
(Vice President Business Development)
Forrest Fuller heads Business Development activities for Bionomics Limited bringing nearly thirty years of early stage biotechnology experience. Dr Fuller previously held key business development or scientific leadership positions at S*BIO, TargeGen, Elitra Pharmaceuticals, Trega Biosciences, NPS Pharmaceuticals and Scios. He has negotiated and managed multiple external collaborations and M&A transactions including the sale of TargeGen to Sanofi-Aventis in 2010 and the sale of all S*BIO assets in 2012. Dr Fuller has extensive experience in intellectual property portfolio management and has helped launch numerous entrepreneurial companies through his work with such programs as UCSD CONNECT and the Governor's Advisory Counsel to the Utah Centers of Excellence Program (COEP). He holds a Bachelor of Science degree in Chemistry (University of Utah) and a PhD in Biochemistry and Molecular Biology (Harvard University).
Dr Andrew Harvey BSc (Hons), PhD
(Vice President Drug Discovery)
Dr Andrew Harvey is Vice President Drug Discovery. Dr Harvey is responsible for all chemistry activities in Bionomics' programs. Prior to joining Bionomics in 2009, Dr Harvey was a medicinal chemist at The Walter and Eliza Hall Institute for Medical Research. He was awarded a National Health and Medical Research Council Industry Fellowship to support his research into new treatments for Multiple Sclerosis. He received his PhD and Bachelor of Science (Honours) in the fields of biological and organic chemistry from Canterbury University in New Zealand.
Dr Gabriel Kremmidiotis BSc (Hons), PhD
(Vice President Research & Development)
Dr Gabriel Kremmidiotis has a diverse scientific background spanning the fields of Drug Discovery & Development, Cancer Biology, Immunology, Molecular Genetics and Bioinformatics. Dr Kremmidiotis has a PhD and a Bachelor of Science (Honours) from Flinders University and a Bachelor of Science from The University of Melbourne. Dr Kremmidiotis joined Bionomics in January 2002. Other appointments have included positions at Flinders University, Adelaide University, the Los Alamos National Laboratories and the Adelaide Women's and Children's Hospital. He is the author of 25 articles published in internationally-recognised scientific journals including Clinical Cancer Research, Molecular Cancer Therapeutics, Cell and Proceedings of the National Academy of Sciences. Dr Kremmidiotis is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
Dr Sue O'Connor PhD
(Vice President Neuroscience Research)
Dr Sue O'Connor graduated from the University of Adelaide, Australia with a PhD in Genetics. With her post-doctoral research at the Hanson Institute, Dr O'Connor moved into the Biotechnology sector, working on drug development projects in the Department of Medicine at Flinders University, Australia. Here, her interest in neuropsychopharmacology and the development of drugs for the treatment of psychiatric disorders was formed. Since joining the Bionomics team 9 years ago, her major focus has been in CNS drug discovery and development. Sue has identified BNC210, a small molecule with considerable potential as a new treatment for anxiety disorders and has taken the molecule through to the completion of four Phase Ia / Ib clinical trials in Australia and Europe. BNC210 has now been partnered with a US pharmaceutical company for further clinical development
Dr Jeremy Simpson BSc (Hons), PhD
(Vice President Clinical Development)
Dr Jeremy Simpson joined Bionomics in July 2012. He holds a Bachelor of Science (Honours) from Cardiff University and a PhD from Brunel University. Dr Simpson has over 20 years of corporate leadership experience in healthcare, pharma and contract research organisation settings across Australia, New Zealand and the Asia Pacific region. Dr Simpson has worked in clinical development roles with Wellcome Australia, Pharmacia Australia and ICON Clinical Research where he led the Asia Pacific regional team whilst based in Singapore. Most recently, Dr Simpson was Scientific Affairs Director at Fresenius Kabi Australia with responsibility for regulatory affair, medical affairs, quality assurance, clinical development and product reimbursement. In 2011 he was awarded the Fresenius Kabi Asia Pacific Management Team Award 2011.
Dr Peter Chu PhD
(Vice President US Operations & Cancer Biology)
Dr Chu is a seasoned biotech industry professional with 20 years experience in medical research and drug discovery. He is a recognised expert on cancer stem cells, and has also published scientific papers in the areas of cancer therapeutics and tumor immunology. He was the founding CEO of Eclipse Therapeutics, and during his tenure, the company successfully raised a $2M seed investment round and acquired Biogen Idec's cancer stem cell assets. Prior to Eclipse, Dr Chu was a scientist at Biogen Idec for 9 years, where he led the cancer stem cells research program, and also held various leadership positions on multiple cancer therapeutic antibody programs. Dr Chu also worked extensively with the business development group to evaluate new licensing and investment opportunities in oncology. Dr Chu received his doctorate from the Biomedical Sciences Program at the University of California, San Diego, and a master's degree from the University of Toronto. His undergraduate degree was in microbiology and immunology at McGill University in Montreal, Canada.
Dr Christopher Reyes PhD
(Vice President Research and Development Cancer Biology)
Christopher Reyes, PhD, brings his experience linking protein biophysics to drug discovery and development to his work at Eclipse. Prior to founding Eclipse, Dr Reyes was a scientist at Biogen Idec charged with the leading multiple antibody therapeutic and engineering programs. Dr Reyes has extensive project management experience and is a co- inventor on numerous patent applications covering antibody engineering and therapeutic antibodies. Dr Reyes received his bachelor's degree in Biophysics from the University of California, Berkeley and performed his graduate studies in Biophysics at the University of California, San Francisco. Dr Reyes was a postdoctoral fellow at The Scripps Research Institute focused on the X-ray crystallography of integral membrane proteins and led a small drug discovery team focused on overcoming multi-drug resistance pathogens. Dr Reyes has received honours from the National Science Foundation, the Ford Foundation and was a McNair Scholar.